

Available online at www.sciencedirect.com



Tetrahedron Letters 46 (2005) 907-910

Tetrahedron Letters

Highly convergent synthesis of a rebeccamycin analog with benzothioeno(2,3-a)pyrrolo(3,4-c)carbazole as the aglycone

Jianji Wang,^{a,*} Nachimuthu Soundarajan,^a Nian Liu,^a Kurt Zimmermann^b and B. Narasimhulu Naidu^b

^aBristol-Myers Squibb Pharmaceutical Research Institute, Process Research & Development, 1 Squibb Drive, New Brunswick, NJ 08903, USA

^bBristol-Myers Squibb Pharmaceutical Research Institute, Drug Discovery, 5 Research Parkway, Wallingford, CT 06492, USA

Received 29 November 2004; revised 15 December 2004; accepted 15 December 2004

Abstract—A highly convergent, scalable synthesis of the rebeccamycin analog 2 was demonstrated in seven steps and 31% overall yield based on the *N*-protected building block dibromomaleimide 7. The practical synthesis of other two building blocks, 5,6-di-fluoro-3-benzothiopheneboronic acid 6 and 5,6-difluoroindole 8, is described. © 2004 Elsevier Ltd. All rights reserved.

1. Introduction

Rebeccamycin 1 and its family members are potent antitumor agents which act by inhibition of protein kinase C and have topoisomerase activity.^{1–3} As part of a program for optimization of their biological activity by modification of both the aglycone and the sugar portions, we required a practical route to the rebeccamycin analog 2 with benzothioeno(2,3-*a*)pyrrolo(3,4-*c*)carbazole as the aglycone. In particular, we were interested in the practical synthesis of the *N*-protected aglycone benzothioeno(2,3-*a*)pyrrolo(3,4-*c*)carbazole 3, which we needed in large quantities. Our highly convergent synthetic strategy is shown in Scheme 1. We envisioned that the β -glycosidic bond in the target molecule **2** could be formed by Mitsunobu coupling of the aglycone **3** with the benzyl protected D-glucopyranose **4**. The key intermediate, *N*-protected benzothioeno(2,3-*a*)pyrrolo(3,4-*c*)carbazole **3**, could be assembled starting from the three building blocks **6**, **7**, and **8**. Consecutive displacement of two bromine atoms in *N*-protected dibromomaleimide **7** by condensation with the magnesium anion of 5,6-difluoroindole (**8**) followed by Suzuki coupling with 5,6-difluoro-3-benzothiopheneboronic acid (**6**) would afford intermediate **5**. Using our new methodology described previously,⁴ the



Keywords: Rebaccamycin analog; Carbazole.

* Corresponding author. Tel.: +1 732 227 6876; fax: +1 732 227 3002; e-mail: jianji.wang@bms.com

0040-4039/\$ - see front matter © 2004 Elsevier Ltd. All rights reserved. doi:10.1016/j.tetlet.2004.12.068



Scheme 1. Retrosynthesis of 2.

oxidative cyclization of the above assembled intermediate **5** should afford the desired aglycone **3**.

As for the three building blocks, the synthesis of *N*-protected dibromomaleimide **7** has been disclosed in our previous publication.⁴ Herein, we disclose a practical synthesis of other two building blocks, 5,6-difluoro-3-benzothiopheneboronic acid (**6**) and 5,6-difluoroindole (**8**). The ultimate assembly of these building blocks into the aglycone, benzothioeno(2,3-*a*)pyrrolo(3,4-*c*)carbazole (**3**) followed by conversion to the final product **2** is described below.

2. Synthesis of 5,6-difluoro-3-benzothiopheneboronic acid 6 (Scheme 2)

The Grignard reagent, derived from reaction of bromide **9** with magnesium, on quenching with sulfur gave a 76% yield of the thiophenol.^{5,6} Treatment with 1-chloro-2,2-diethoxyethane afforded the acetal in 95% yield. Cyclization of the crude acetal with PPA in chlorobenzene gave 5,6-difluorobenzothiophene (**10**) in 67% yield. Bromination (Br₂)^{7–9} of **10** gave the expected **11** in low yield (38%). The major impurity was identified as 2,3-dibromo-5,6-difluorobenzothiophene. With NBS as the

brominating reagent, significantly less of the dibromide impurity was formed. Bromination of 5,6-difluorobenzothiophene (**10**) with 1.2 equiv of NBS in a mixture of solvents (acetic acid, 10% by v/v in α, α, α -trifluorotoluene) at 80 °C for 4 h afforded **11** in 71% yield. A solvent effect was observed during the preparation of boronic acid **6**; *tert*-butyl methyl ether in place of THF gave much better quality and yield of the product. Lithium–bromine exchange of bromide **11** with *n*-BuLi at -80 °C in *tert*-butyl methyl ether followed by quenching the resulting anion with trimethyl borate, then hydrolysis of the crude borate with 3 N HCl, completed the synthesis of 5,6-difluoro-3-benzothiopheneboronic acid **6**, obtained as a white solid in five steps and 25% overall yield from **9**.

3. Synthesis of 5,6-diffuoroindole 8 (Scheme 3)

Iodination of 3,4-difluoroaniline (12) with ICl in acetic acid gave 2-iodo-4,5-difluoroaniline in 96% yield.^{10,11} Without further purification, protection of the amino group by reaction with chloromethylformate afforded carbamate 13 in 89% yield. Heck coupling of carbamate 13 with trimethylsilylacetylene mediated by $Pd(OAc)_2$ (1.5% mol) and tris-*o*-tolylphosphine (2.0% mol) in Et₃N afforded acetylenide 14 in 94% yield. Treatment



Scheme 2. Reagents and conditions: (a) 1. Mg, 2. Sulphur, 76%; (b) CICH₂CH(OEt)₂, EtONa, reflux 36 h, 95%; (c) PPA, PhCl, reflux, 3 h, 67%; (d) NBS, 1.2 equiv, AcOH, 80 °C, 4 h, 71%; (e) 1. *n*-BuLi, 1.08 equiv, -80 °C, 30 min, 2. B(OMe)₃, 2.4 equiv, -80 °C, 1 h, 3. HCl, 3 N, rt, 1.5 h, 72%.



Scheme 3. Reagents and conditions: (a) ICl, HOAc, rt, 0.5 h, 96%; (b) ClCOOMe, pyridine, 0 °C, 2 h, 89%; (c) Pd(OAc)₂, 1.5 mol%, (*o*-tolyl)₃P, 2.0 mol%, EtN₃, TMSacetylene, rt, 16 h, 94%; (d) EtONa, EtOH, 70 °C, 14 h, 82%.



Scheme 4. Reagents and conditions: (a) 1. EtMgBr, 2. 7, rt, 3 h, then 50 °C, 2 h, 91%; (b) 6, PdCl₂(PPh₃)₂, 20 mol%, Na₂CO₃, DME/EtOH, 5:1, reflux 2 h, 82%; (c) air, Pd(OAc)₂, 5 mol%, CuCl₂, 100 mol%, 90 °C, 6 h, 70%.



Scheme 5. Reagents and conditions: (a) PPh₃, 1.5 equiv, DIAD, 1.5 equiv, THF, rt, 20 h, 95%; (b) Pd(OH)₂/C, cyclohexene, EtOH, reflux 7 h; (c) KOH, 4.45 equiv, EtOH, 30 °C 16 h; then conc. HCl, pH < 1.5, 80%; (d) HN(TMS)₂, 10 equiv, MeOH, rt, 6 h, 78%.

of 14 with EtONa (70 °C, 14 h) in EtOH^{12,13} completed the synthesis of another building block, 5,6-difluoro-indole (7) in four steps and 66% yield.

4. Assembly of 6, 7, and 8 into the key intermediate 3 (Scheme 4)

With the three building blocks 6, 7, 8 in hand, we embarked on their assembly and conversion to the key intermediate 3. Reaction of 5,6-difluoroindole 8 with Nprotected dibromomaleimide 7 mediated by EtMgBr at 40 °C for 8 h afforded the bromide 15 in 91% yield. Protection of the indole nitrogen was not necessary for the subsequent Suzuki coupling reaction. The cross-coupling of 15 with boronic acid 6 catalyzed by PdCl₂(PPh₃)₂ and Na_2CO_3 as the base gave the coupled product 5 in 82% yield. Oxidative cyclization of 5 using DDQ^{14,15} gave the expected product 3, but in low isolated yield (<50%) due to the poor solubility of 3 and the resultant difficulties in removing reduced DDQ. As an alternative, using atmospheric O₂ as the stoichiometric oxidant and $Pd(OAc)_2$ (5 mol%)/CuCl₂ (100 mol%) as the catalysts,⁴ afforded the key intermediate 3 in three steps and 52%overall yield from the building block 8.

5. Synthesis of the target molecule 2 (Scheme 5)

As expected,^{16,17} Mitsunobu coupling of the aglycone **3** with 2,3,4,6-tetra-*O*-benzyl-D-glucopyranose **4** gave almost exclusively the β -anomer **17** in 95% yield. The four benzyl protecting groups in **17** were removed by hydrogenation on Pd(OH)₂/C in the presence of cyclohexene.

Without further purification, treatment with 4.45 equiv of KOH in EtOH for 16 h at 30 °C followed by HCl acidification (pH < 1.5) afforded anhydride **18** in 80% yield. Reaction of **18** with 10 equiv of HN(TMS)₂ in MeOH at rt for 6 h accomplished our synthesis of target molecule **2**¹⁸ in four steps and 59% yield from the key intermediate **3**.

In summary, we have developed a convergent, scalable synthesis of 2 in seven steps and 31% overall yield based on the *N*-protected building block dibromomaleimide 7. We also demonstrated the practical synthesis of the two building blocks 5,6-difluoro-3-benzothiophenebronic acid (6) and 5,6-difluoroindole (8).

Acknowledgements

The authors would like to thank Drs. James Sherbine, David Kronenthal, and Richard Mueller for helpful discussions.

References and notes

- 1. Lon, B. H.; Balasubramanian, B. N. Exp. Opin. Ther. Pat. 2000, 10, 635.
- 2. Steglich, W. Pure Appl. Chem. 1989, 61, 281.
- Gribble, G. W.; Berthel, S. J. In *Stud. Nat. Prod. Chem.*; Atta-ur-Rahman, Ed.; Elsevier Science: Amsterdam, 1993; Vol. 12.
- Wang, J.; Rosingana, M.; Watson, D.; Dowdy, E.; Discordia, R.; Soundarajan, N.; Li, W. *Tetrahedron Lett.* 2001, 42, 8935.

- 5. Thomas, P. J.; Gonzalez, M. A.; Pews, R. G. Synth. Commun. 1995, 25, 2813.
- Sato, R.; Utsumi, Y.; Nakajo, S.; Kawai, Y. *Heterocycles* 2001, 55, 851.
- 7. Cherry, W. H.; Craig, J. T.; Porter, Q. N. Aust. J. Chem. 1979, 32, 133.
- 8. Clementi, S.; Linda, P.; Marino, G. J. Chem. Soc. 1971, B, 79.
- 9. Campaigne, E.; Dinner, A.; Haseman, M. J. Heterocycl. Chem. 1971, 8, 755.
- 10. Kosynkin, D. V.; Tour, J. M. Org. Lett. 2001, 3, 991.
- Garden, S. J.; Torres, J. C.; De Souza Melo, S. C.; Lima, A. S.; Pinto, A. C.; Lima, E. L. S. *Tetrahedron Lett.* 2001, 42, 2089.
- 12. Dai, W.-M.; Guo, D.-S.; Sun, L.-P. Tetrahedron Lett. 2001, 42, 5275.
- 13. Sakamoto, T.; Kondo, Y.; Iwashita, S.; Yamanaka, H. *Chem. Pharm. Bull.* **1987**, *35*, 1823.
- Joyce, R. P.; Gainor, J. A.; Weinreb, S. M. J. Org. Chem. 1987, 52, 1177.
- 15. Ohkubo, M.; Nishimura, T.; Jona, H.; Honma, T.; Morishima, H. *Tetrahedron* **1996**, *52*, 8099.

- Zembower, D. E.; Zhang, H.; Lineswala, J. P.; Kuffel, M. J.; Aytes, S. A.; Ames, M. M. *Bioorg. Med. Lett.* **1999**, *9*, 145.
- Ohkubo, M.; Nishimura, T.; Jona, H.; Ito, S.; Morishima, H. *Tetrahedron* 1997, *53*, 5937.
- 18. Selected MS and ¹H NMR data: Building block boronic acid **6**: MS: $(M+H)^+$ 215; ¹H NMR (500 MHz, DMSO*d*₆): δ 9.3 (s, 2H), 8.35 (dd, J = 8.2, 12.9, 1H), 8.33 (s, 1H), 8.21 (dd, J = 8.5, 11.4, 1H) ppm. Building block 5,6difluoroindole **8**: MS: $(M+H)^+$ 154; ¹H NMR (500 MHz, CDCl₃): δ 8.12 (s, 1H, N–H), 7.49 (dd, J = 7.7, 10.3, 1H), 7.25 (d, J = 2.9, 1H), 7.40 (dd, J = 7.0, 11.3, 1H), 6.51 (d, J = 2.9, 1H) ppm. Compound **3**: $(M+H)^+$ 561; ¹H NMR (500 MHz, THF-*d*₈) δ 11.63 (s, 1H), 9.74 (dd, J = 12.4,8.1 Hz, 1H), 8.92 (dd, J = 10.8, 8.4 Hz, 1H), 7.88–7.85 (m, 1H), 7.45 (d, J = 8.1 Hz, 2H), 7.40–7.35 (m, 3H), 4.88 (s, 2H), 1.3 (s, 9H) ppm. Final product **2**: MS: yellow solid; $(M+H)^+$ 577; ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.52, 11.48 (s, 1H), 9.74, 9.48 (dd, J = 12.7, 8.1 Hz, 1H), 8.95, 8.91 (dd, J = 11.2, 8.5 Hz, 1H), 8.31, 8.00 (dd, J = 10.3,7.7 Hz, 1H), 8.22, 7.90 (dd, J = 12.2, 6.9 Hz, 1H), 6.14, 6.05 (d, J = 8.9 Hz, 1H), 5.30–4.78 (br s, 2H), 4.08–3.28 (m, 8H) ppm.